Welcome to our dedicated page for Edgewise Therapeutics news (Ticker: $EWTX), a resource for investors and traders seeking the latest updates and insights on Edgewise Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Edgewise Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Edgewise Therapeutics's position in the market.
Rhea-AI Summary
Edgewise Therapeutics, Inc. (EWTX) reports significant progress in advancing muscle-targeted therapeutics with positive financial results and recent business highlights. The company raised $232M in net proceeds, strengthening its balance sheet. They are focusing on developing EDG-5506 for Becker and Duchenne muscular dystrophy, with ongoing trials showing promising results. They are also working on EDG-7500 for hypertrophic cardiomyopathy, further enhancing their pipeline.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.74%
Tags
-
Rhea-AI Summary
Edgewise Therapeutics, Inc. (Nasdaq: EWTX) receives FDA Fast Track designation for EDG-5506, an investigational treatment for Duchenne and Becker muscular dystrophy. The drug aims to prevent muscle damage in dystrophinopathies, highlighting the urgent need for new therapeutic options for rare muscle disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.21%
Tags
-
Rhea-AI Summary
Edgewise Therapeutics, Inc. (NASDAQ: EWTX) has announced the pricing of an underwritten offering of 21,818,182 shares of its common stock at an offering price of $11.00 per share, expecting to generate approximately $240 million. The company plans to use the net proceeds to support various clinical trials and research and development programs, as well as for general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
34.57%
Tags
Rhea-AI Summary
Edgewise Therapeutics, Inc. (EWTX) to Present at 42nd Annual J.P. Morgan Healthcare Conference, Highlights 2023 Accomplishments and 2024 Milestones
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.76%
Tags
-
Rhea-AI Summary
Edgewise Therapeutics, Inc. (Nasdaq: EWTX) will present at the J.P. Morgan 42nd Annual Healthcare Conference on January 9, 2024. The presentation will be webcast live and accessible for replay. Users are advised to connect to the webcast early for a timely connection.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.1%
Tags
-
Rhea-AI Summary
Edgewise Therapeutics, Inc. (Nasdaq: EWTX) launches an educational website dedicated to the Becker muscular dystrophy (Becker) community, providing resources to help individuals and caregivers better understand the disease. Becker is a serious neuromuscular condition with no approved therapies, impacting an estimated 5,000 individuals in the United States. The website aims to provide support, advocacy partnerships, and available services for the Becker community.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.23%
Tags
Rhea-AI Summary
Edgewise Therapeutics, Inc. (Nasdaq: EWTX) has received Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) from the FDA for its investigational drug EDG-5506 for the treatment of Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). EDG-5506 is currently advancing in multiple Phase 2 trials for individuals with Duchenne, Becker, and other dystrophinopathies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.88%
Tags
-
News
Rhea-AI Summary
EWTX: Edgewise Therapeutics, Inc. Reports Progress in Muscular and Cardiovascular Programs with Initiatives Including EDG-5506 Trials for Becker and Duchenne Muscular Dystrophy and Phase 1 Trial of EDG-7500 for Hypertrophic Cardiomyopathy
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.29%
Tags
-
Rhea-AI Summary
Edgewise Therapeutics, Inc. (Nasdaq: EWTX) announced participation in upcoming investor conferences, including the Stifel 2023 Healthcare Conference on November 15, 2023, and the Piper Sandler 35th Annual Healthcare Conference on November 29, 2023. The presentations will be webcast live and accessible for replay. It is recommended to connect to the webcasts several minutes prior to the start for a timely connection.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
News
Rhea-AI Summary
Edgewise Therapeutics, Inc. (Nasdaq: EWTX) will present the results of nonclinical studies of EDG-7500 at the American Heart Association’s (AHA) Scientific Sessions 2023. EDG-7500 is a first-in-class oral, selective, cardiac sarcomere modulator designed to address cardiac relaxation issues. The presentations will focus on the improvement of cardiac function and reserve in a minipig model of hypertrophic cardiomyopathy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.78%
Tags
Edgewise Therapeutics, Inc.
Nasdaq:EWTX
EWTX Rankings
EWTX Stock Data
1.65B
51.74M
0.44%
97.84%
6.15%
Medicinal and Botanical Manufacturing
Manufacturing
United States of America
BOULDER
About EWTX
edgewise therapeutics is a biotechnology company focused on developing novel therapies for diseases involving skeletal muscle. the company is headquartered in boulder, co and received its series a financing from orbimed.